• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets.

作者信息

Pfaff Elke, Adam de Beaumais Tiphaine, Marchais Antonin, van Tilburg Cornelis M, Blattner-Johnson Mirjam, Dirksen Uta, Øra Ingrid, Geoerger Birgit, Schleiermacher Gudrun, Pfister Stefan M, Witt Olaf, Jones David T W, Vassal Gilles

机构信息

Elke Pfaff, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Tiphaine Adam de Beaumais, MD, Clinical Research Department, Gustave Roussy Cancer Center, Villejuif, France; Antonin Marchais, PhD, Bioinformatics and INSERM U1015, Gustave Roussy Cancer Center, University Paris-Saclay, Villejuif, France; Cornelis M. van Tilburg, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany German Cancer Consortium (DKTK), Germany; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany; Mirjam Blattner-Johnson, PhD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany; Uta Dirksen, MD, German Cancer Consortium (DKTK), Partner Essen, Germany; University Hospital Essen, Pediatrics III, Hematology and Oncology, West German Cancer Centre, Essen, Germany; Ingrid 00D8ra, MD, PhD, Department of Pediatric Oncology and Hematology, Karolinska University Hospital, Solna, Sweden; Skane University Hospital, Lund, Sweden; Birgit Geoerger, MD, PhD, Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, INSERM U1015, University Paris-Saclay, Villejuif, France; Gudrun Schleiermacher, MD, Equipe SiRIC RTOP Recherche Translationelle en Oncologie Pédiatrique, Institut Curie, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France; Stefan M. Pfister, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Olaf Witt, MD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany; KiTZ Clinical Trial Unit, Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany; David T. W. Jones, PhD, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany; and Gilles Vassal, MD, PhD, Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France.

出版信息

JCO Precis Oncol. 2021 Nov;5:450-454. doi: 10.1200/PO.20.00417.

DOI:10.1200/PO.20.00417
PMID:34994601
Abstract
摘要

相似文献

1
Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets.通过欧洲临床测序项目确定的儿科高危恶性肿瘤的改变构成了有前景的药物靶点。
JCO Precis Oncol. 2021 Nov;5:450-454. doi: 10.1200/PO.20.00417.
2
Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib.在入组研究拉罗替尼的临床试验之前,用于鉴定具有 TRK 融合癌的患者的诊断检测方法。
Cancer Genet. 2022 Jan;260-261:46-52. doi: 10.1016/j.cancergen.2021.11.006. Epub 2021 Dec 5.
3
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.ESMO 关于在日常实践和临床研究中检测 NTRK 融合的标准方法的建议。
Ann Oncol. 2019 Sep 1;30(9):1417-1427. doi: 10.1093/annonc/mdz204.
4
Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.多学科共识:优化肿瘤中 NTRK 基因改变的检测。
Clin Transl Oncol. 2021 Aug;23(8):1529-1541. doi: 10.1007/s12094-021-02558-0. Epub 2021 Feb 23.
5
NTRK-Rearranged soft tissue neoplasms: A review of evolving diagnostic entities and algorithmic detection methods.NTRK 重排软组织肿瘤:不断演变的诊断实体和算法检测方法的综述。
Cancer Genet. 2022 Jan;260-261:6-13. doi: 10.1016/j.cancergen.2021.10.007. Epub 2021 Nov 3.
6
Fusions in Central Nervous System Tumors: A Rare, but Worthy Target.中枢神经系统肿瘤中的融合基因:一种罕见但值得关注的靶点。
Int J Mol Sci. 2020 Jan 23;21(3):753. doi: 10.3390/ijms21030753.
7
[Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].[药物批准:恩曲替尼和拉罗替尼——具有NTRK融合的癌症]
Bull Cancer. 2020 Nov;107(11):1085-1086. doi: 10.1016/j.bulcan.2020.09.009. Epub 2020 Oct 21.
8
NTRK fusions and Trk proteins: what are they and how to test for them.NTRK 融合基因与 Trk 蛋白:它们是什么,以及如何检测它们。
Hum Pathol. 2021 Jun;112:59-69. doi: 10.1016/j.humpath.2021.03.007. Epub 2021 Mar 29.
9
NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.NTRK 融合分析显示中东 BRAF 野生型 PTC 中存在富集。
Eur J Endocrinol. 2021 Apr;184(4):503-511. doi: 10.1530/EJE-20-1345.
10
NTRK point mutations and their functional consequences.神经营养酪氨酸激酶受体(NTRK)点突变及其功能后果。
Cancer Genet. 2022 Apr;262-263:5-15. doi: 10.1016/j.cancergen.2021.12.002. Epub 2021 Dec 16.

引用本文的文献

1
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.携带NTRK基因融合的中枢神经系统肿瘤的临床特征与预后
Clin Cancer Res. 2025 Feb 3;31(3):561-572. doi: 10.1158/1078-0432.CCR-24-0581.
2
Neurotrophin signalling in the human nervous system.人类神经系统中的神经营养因子信号传导
Front Mol Neurosci. 2023 Jul 4;16:1225373. doi: 10.3389/fnmol.2023.1225373. eCollection 2023.